The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion
Research output: Contribution to journal › Journal article › Research › peer-review
BACKGROUND/AIMS: Inhibition of dipeptidyl peptidase 4 by vildagliptin enhances the concentrations of the active form of the incretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP). The present study asked whether vildagliptin accentuates glibenclamide-induced hypoglycemia or affects endogenous secretion of GLP-1 and GIP after an oral glucose tolerance test.
METHODS: There were 16 healthy male subjects studied on four occasions after an overnight fast in a double-blind, four-way crossover study. In random order, vildagliptin (100 mg) or placebo, with and without glibenclamide (5 mg), was administered 30 min before 75 g oral glucose. Blood was sampled to measure glucose, and total (sum of active and inactive) GLP-1 and GIP. Statistical evaluation was done using repeated-measures ANOVA.
RESULTS: Glibenclamide provoked hypoglycemia (<or=1.9 mm), but this was not accentuated by the simultaneous administration of vildagliptin (P = 0.25). The integrated incremental responses of total GLP-1 were reduced by vildagliptin by 72% (with glibenclamide) and 48% (without glibenclamide) (effect of vildagliptin: P < 0.0001; glibenclamide: P = 0.31; interaction: P = 0.26). Similarly, integrated incremental responses of total GIP were reduced by vildagliptin by 26 and 21%, with and without glibenclamide, respectively (vildagliptin: P = 0.017; glibenclamide: P = 0.44; interaction: P = 0.69).
CONCLUSIONS: Sulfonylurea-induced hypoglycemia after the oral administration of glibenclamide is not accentuated by the coadministration of vildagliptin. This may be explained by a negative feedback regulation of GLP-1 and GIP secretion that limits the degree to which the active incretin levels are enhanced.
Original language | English |
---|---|
Journal | The Journal of clinical endocrinology and metabolism |
Volume | 92 |
Issue number | 11 |
Pages (from-to) | 4165-71 |
Number of pages | 7 |
ISSN | 0021-972X |
DOIs | |
Publication status | Published - Nov 2007 |
- Adamantane, Adult, Algorithms, C-Peptide, Dipeptidyl-Peptidase IV Inhibitors, Drug Interactions, Enzyme-Linked Immunosorbent Assay, Gastric Emptying, Gastric Inhibitory Polypeptide, Glucagon, Glucagon-Like Peptide 1, Glucose, Glyburide, Humans, Hydrocortisone, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Nitriles, Pyrrolidines
Research areas
ID: 132049840